Repeated effectiveness claims in the risk section may dilute required side-effect emphasis

AI-verifiedwarningBinding lawRaised as a question — a person decides

Rule

Under 21 CFR 202.1(e)(7), a prescription drug advertisement may be found lacking in fair balance or otherwise misleading where, within a distinct part of the advertisement that contains the side effect and contraindication information, repetition or other emphasis of effectiveness or safety claims within that same part diminishes the emphasis given to the side effect and contraindication information. This applies to advertisements as defined in 21 CFR 202.1(l)(1) (e.g., journal ads, broadcast ads) and not to brochures, detail pieces, mailers, or similar items that 21 CFR 202.1(l)(2) treats as labeling rather than advertising.

Check

Identify whether the advertisement sets off side effect/contraindication information in a distinct part (e.g., a boxed or clearly separated risk section). Within that same part, check whether effectiveness or safety claims are repeated or given emphasis (through repetition, typography, placement, or other techniques) to a degree that diminishes the prominence or emphasis given to the risk information in that part. A violation is suggested when effectiveness/safety language recurs or is visually emphasized within the risk section while the adjacent side effect/contraindication text appears comparatively de-emphasized.

Escalate when

Whether the degree of repetition or emphasis of effectiveness/safety claims within the risk section actually diminishes emphasis on the risk information is a matter of visual and editorial judgment requiring human review.

Where this comes from

21 CFR 202.1(e)(7)(vii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ct of which substantially invalidate the application of statistical analyses, interpretations, or evaluations. (vi) Contains claims concerning the mechanism or site of drug action that are not generally regarded as established by scientific evidence by experts qualified by scientific training and experience without disclosing that the claims are not established and the limitations of the supporting evidence. (vii) Fails to provide sufficient emphasis for the information relating to side effects and contraindications, when such information is contained in a distinct part of an advertisement, because of repetition or other emphasis in that part of the advertisement of claims for effectiveness or safety of the drug. (viii) Fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis. (ix) Fails to provide adequate …

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Document typeadvertisement

Risk info placementdistinct-part

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Quote is verbatim from 21 CFR 202.1(e)(7)(vii) and the locator is exact; the rule's substantive reading is faithful — it correctly requires that the repetition/emphasis of effectiveness or safety claims occur 'in that part' (the distinct risk section), and it preserves the 'when such information is contained in a distinct part of an advertisement' precondition rather than dropping it.
- Overstated on normative force: the source paragraph is headed 'Advertisements that may be false, lacking in fair balance, or otherwise misleading' and its stem reads 'An advertisement may be false, lacking in fair balance, or otherwise misleading ... if it:'. This is the (e)(7) permissive list, deliberately contrasted in the same regulation with the (e)(6) list of advertisements that are false/lacking fair balance. The rule states the item as a flat obligation ('must not crowd out'), converting a may-be-misleading factor into a per se prohibition.
- applies_when is under-limited: 21 CFR 202.1 governs prescription-drug advertisements, and (l)(1)-(2) of the same source distinguishes advertisements from materials deemed labeling. A bare 'promotional' tag extends the rule to OTC and to pieces the regulation classifies as labeling. The provision's reference to a 'distinct part of an advertisement' is also print/space-ad framed.
- Atomic: one failure mode (emphasis dilution of risk info within the distinct risk part caused by repeated/emphasized efficacy or safety claims); no bundled independent requirements.
- determinism 'judgment' is correct — 'sufficient emphasis' and degree of dilution turn on impression and layout, not presence/absence or literal match; the escalation note is consistent.
- authority 'binding' is correct — codified federal regulation, not guidance.
- Severity 'warning' is defensible and in fact well matched to the (e)(7) 'may be' framing; the rule statement's wording is what is out of step with the severity, not the other way round.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is a verbatim, complete rendering of 21 CFR 202.1(e)(7)(vii), and the locator matches the enumerated subparagraph exactly as it appears in the source text.
- The rule statement preserves the regulation's hedged framing. The source's chapeau for paragraph (e)(7) reads 'An advertisement may be false, lacking in fair balance, or otherwise misleading or otherwise violative of section 502(n) of the act if it:', and the rule says an ad 'may be found lacking in fair balance or otherwise misleading where...'. No permissive provision has been converted into an absolute prohibition.
- The added scoping sentence about 202.1(l)(1) and (l)(2) is directly supported by the excerpt, which lists journal/broadcast advertisements as subject to 502(n) and expressly determines brochures, detailing pieces, mailing pieces, etc., to be labeling. This is a genuine limit drawn from the source, not an invention.
- applies_when is well justified and not over- or under-scoped: the provision is expressly conditioned on the risk information being 'contained in a distinct part of an advertisement', which maps to risk-info-placement=distinct-part and document-type=advertisement. The promotional flag follows from the subject matter being prescription-drug advertising under 502(n).
- Atomic: the rule tests one condition only — whether repetition/other emphasis of effectiveness or safety claims inside the distinct risk part deprives the side-effect and contraindication information of sufficient emphasis. It does not bundle in the separate, distinct obligations in (e)(7)(viii) (comparable prominence/readability), (ix) (facing pages), (xi), or (xii).
- determinism=judgment is correct: 'sufficient emphasis' and whether emphasis is 'diminished' are inherently impressionistic assessments of prominence and balance that no literal presence/absence test can settle. The escalate-when note correctly flags this for human review.
- authority=binding is correct: 21 CFR 202.1 is a codified regulation, not guidance.
- severity=warning is defensible. Unlike paragraph (e)(6), which lists conduct that renders an advertisement violative, paragraph (e)(7) is framed as conduct that 'may be' false or lacking in fair balance — a factor-based, non-categorical list — so a flag-for-review severity rather than a hard failure is appropriate.
- Minor, non-blocking: the check's parenthetical 'typography, placement, or other techniques' borrows vocabulary from (e)(7)(viii) rather than (vii), but (vii)'s own phrase 'repetition or other emphasis' fairly encompasses those techniques, so the check does not exceed the cited provision. Likewise the closing sentence of the check is conditioned on the risk text appearing 'comparatively de-emphasized', so it does not treat mere recurrence of effectiveness language as sufficient.